Highlights Newsletter 2
This newsletter presents you the following key sessions:
1. Podcast with Prof. Satva Neelapu about Axi-cel for patients with R/R indolent non-Hodgkin lymphoma:
the ZUMA-5 study
2. High rates of sustained transfusion independence following gene transfer in patients with β-Thalassemia Major
3. COVID-19 vaccination least effective in patients with lymphoid malignancies
4. Polatuzumab vedotin plus R-CHP as first line treatment for patients with diffuse large B-cell lymphoma
5. Discontinuation of tyrosine kinase inhibitor therapy in CML: Final results of EURO-SKI